ArticleScientific reports2025
Uncovering mechanism of hepatotoxicity diseases caused by tetrahydrocannabinol based on novel network toxicology and experimental verification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study systematically investigated the molecular mechanisms underlying tetrahydrocannabinol (THC)-induced hepatotoxicity in humans through an integrated approach combining network toxicology, molecular docking, and experimental validation. Our analysis identified 22 core targets associated with THC-mediated hepatotoxicity. Protein-protein interaction (PPI) network analysis revealed significant functional associations among these 22 potential target proteins. KEGG pathway and GO term analyses demonstrated that THC potentially exerts hepatotoxic effects through multiple biological processes, including endocrine resistance, bile secretion, negative regulation of apoptosis, and cellular oxidant detoxification. Disease enrichment analysis further identified several pathological conditions closely associated with THC-induced hepatic damage. Molecular docking simulations demonstrated strong binding affinities between THC and functional domains of 17 target proteins that participated in the aforementioned enriched pathways. An in vitro model of THC-induced hepatocyte injury was successfully established and subsequently validated through RT-qPCR experiment. THC exposure significantly altered the expression patterns of 10 critical target genes: ERBB2, GPX1, MAPK14, NR1H4, SOD1, CXCR2, PPARG, EGFR, TYMS and KDR. The hepatotoxic effects of THC appear to arise from the synergistic interplay of multiple pathways and the coordinated dysfunction of various gene products. These findings elucidate key molecular pathways and therapeutic targets associated with THC-induced hepatotoxicity, providing a theoretical foundation for developing clinical interventions and hepatoprotective strategies against cannabis-related liver damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.